In brief
- The confirmatory phase 3 trial (MAPP2), published in Nature Medicine in 2023, found that MDMA-assisted therapy reduces PTSD symptoms more effectively than a placebo combined with the same psychotherapy.
- After treatment, 71.2% of the MDMA group no longer met the diagnostic criteria for PTSD, compared to 47.6% in the placebo group.
- These are solid but limited results: the sample size is small, the treatment is inseparable from intensive therapeutic support, and in 2024, the US regulatory agency requested more data before granting approval.
MDMA has been studied for years as an adjunct to psychotherapy for post-traumatic stress disorder (PTSD). In 2023, a second phase 3 trial confirmed what a previous 2021 study had already suggested: when combined with structured therapy sessions, the substance improves symptoms in a clinically relevant way for people with moderate to severe PTSD. It is a promising sign, but one that should be read with precision.
The study
The work was published in Nature Medicine (Mitchell et al., 2023) and is known as MAPP2, the confirmatory trial of the phase 3 program. It was a randomized, double-blind, placebo-controlled study. Of the 121 people included, 104 were randomly assigned to two groups of 52: one received MDMA (80-120 mg, with a possible supplemental dose) during three spaced sessions; the other received a placebo. It is key to understand that both groups followed the same psychotherapy program: what was being compared was not “MDMA versus nothing,” but “therapy with MDMA versus therapy with placebo.” The sample was relatively diverse for this field (about one-third of participants were non-white and around 27% were of Hispanic/Latino origin), an important detail because previous mental health studies have often been biased toward white populations.
What was found
The primary measure was the CAPS-5 scale, the standard for quantifying the severity of PTSD. The mean reduction was 23.7 points in the MDMA group versus 14.8 in the placebo group, a statistically significant difference (p<0.001) with a moderate-to-high effect size (Cohen’s d = 0.7). In a secondary measure of functional impairment (Sheehan Disability Scale), the improvement was also greater with MDMA (p=0.03), though with a more modest effect. Translated into clinical outcomes: after treatment, 71.2% of those who received MDMA no longer met the diagnostic criteria for PTSD (compared to 47.6% with placebo) and 46.2% achieved remission (compared to 21.4%). Regarding safety, there were no serious adverse events; seven people experienced intense adverse effects (five in the MDMA group), and—a relevant detail in a high-risk population—no increase in suicidal ideation attributable to the substance was observed.
What it means (and what it doesn’t)
The finding is consistent: two independent phase 3 trials point in the same direction, which is unusual in mental health research, where many treatments fail to replicate. It is also notable that a good portion of the placebo group improved, which serves as a reminder that the therapeutic framework—the support, preparation, and integration of the sessions—carries significant weight on its own. That is the first limitation: these results do not suggest that taking MDMA on one’s own treats PTSD. What was evaluated is a complete clinical protocol, with supervision, in a controlled environment, and with a therapeutic team during sessions lasting several hours. Separating the drug from that context would be a misinterpretation of the data.
There are more nuances. The sample remains small (about a hundred people) and the follow-up was weeks, not years, so long-term durability has yet to be established. The double-blind design is difficult to maintain with such a perceptible psychoactive substance: many participants intuit what they received, and that “unblinding” can inflate expectations. And on the regulatory front, it is best to be honest in both directions: despite these results, in August 2024, the US FDA did not approve the application and requested an additional trial to resolve questions regarding methodology and safety. It is not a rejection of the hypothesis, but it is a reminder that “promising” does not equate to “proven” or “available.”
A sensible reading, from a harm reduction perspective, is intermediate. MDMA-assisted therapy is one of the most serious and well-documented lines of current psychedelic research, with signs of efficacy that are difficult to ignore for a disorder where available treatments help many people but leave many others behind. At the same time, it is not a miracle cure or a shortcut: it is a demanding clinical procedure, still under evaluation, whose real value will depend on future studies confirming its efficacy, its long-term safety, and the specific conditions under which it works.
Source
- Mitchell JM, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02565-4
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
